136 related articles for article (PubMed ID: 22795584)
41. Comparison of cisplatin-5-fluorouracil-folinic acid versus modified docetaxel-cisplatin-5-fluorouracil regimens in the first-line treatment of metastatic gastric cancer.
Kos FT; Uncu D; Ozdemir N; Budakoglu B; Odabaş H; Abali H; Oksuzoglu B; Aksoy S; Zengin N
Chemotherapy; 2011; 57(3):230-5. PubMed ID: 21597287
[TBL] [Abstract][Full Text] [Related]
42. A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy.
Jeung HC; Rha SY; Im CK; Shin SJ; Ahn JB; Yang WI; Roh JK; Noh SH; Chung HC
Cancer; 2011 May; 117(10):2050-7. PubMed ID: 21523716
[TBL] [Abstract][Full Text] [Related]
43. Randomized phase II trial of two different schedules of docetaxel plus cisplatin as first-line therapy in advanced nonsmall cell lung cancer.
Park SH; Choi SJ; Kyung SY; An CH; Lee SP; Park JW; Jeong SH; Cho EK; Shin DB; Hoon Lee J
Cancer; 2007 Feb; 109(4):732-40. PubMed ID: 17211861
[TBL] [Abstract][Full Text] [Related]
44. A phase II study of concurrent chemoradiotherapy with weekly docetaxel and cisplatin in advanced oesophageal cancer.
Shim HJ; Kim DE; Hwang JE; Bae WK; Nam TK; Na KJ; Cho SH; Chung IJ
Cancer Chemother Pharmacol; 2012 Nov; 70(5):683-90. PubMed ID: 22932694
[TBL] [Abstract][Full Text] [Related]
45. A randomized phase II study of weekly docetaxel/cisplatin versus weekly docetaxel/oxaliplatin as first-line therapy for patients with advanced gastric cancer.
Kim YS; Sym SJ; Park SH; Park I; Hong J; Ahn HK; Park J; Cho EK; Lee WK; Chung M; Lee JH; Shin DB
Cancer Chemother Pharmacol; 2014 Jan; 73(1):163-9. PubMed ID: 24202666
[TBL] [Abstract][Full Text] [Related]
46. Bevacizumab plus docetaxel and cisplatin for metastatic breast cancer: a pilot phase II study.
Tai CJ; Chen CS; Hung CS; Kuo LJ; Wei PL; Chiou JF; Hsu CH; Chiou HY; Wu CH
Anticancer Res; 2012 Dec; 32(12):5501-6. PubMed ID: 23225458
[TBL] [Abstract][Full Text] [Related]
47. A phase II study of pemetrexed combined with cisplatin in patients with recurrent or metastatic nanopharyngeal carcinoma.
Yau TK; Shum T; Lee AW; Yeung MW; Ng WT; Chan L
Oral Oncol; 2012 May; 48(5):441-4. PubMed ID: 22206807
[TBL] [Abstract][Full Text] [Related]
48. Favourable prognosis with modified dosing of docetaxel and cisplatin in Japanese patients with ovarian cancer.
Aoki D; Watanabe Y; Jobo T; Ushijima K; Hasegawa K; Susumu N; Suzuki N; Aoki R; Isonishi S; Sagae S; Ishizuka B; Kamura T; Udagawa Y; Hoshiai H; Ohashi Y; Ochiai K; Noda K
Anticancer Res; 2009 Feb; 29(2):561-6. PubMed ID: 19331203
[TBL] [Abstract][Full Text] [Related]
49. [Docetaxel-cisplatin-5-FU combination chemotherapy as a first-line treatment in patients with metastatic or recurred gastric cancer].
Kang SH; Kim JI; Goh PG; Hwang SW; Kwon DS; Nam KW; Kang HM; Kang YS; Moon HS; Kim SH; Seong JK; Lee BS; Jeong HY
Korean J Gastroenterol; 2007 Sep; 50(3):157-63; discussion 207-9. PubMed ID: 17885280
[TBL] [Abstract][Full Text] [Related]
50. Maintenance immunotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck.
Recchia F; Candeloro G; Di Staso M; Necozione S; Bisegna R; Bratta M; Tombolini V; Rea S
J Immunother; 2008 May; 31(4):413-9. PubMed ID: 18391754
[TBL] [Abstract][Full Text] [Related]
51. Phase II trial of docetaxel combined with nedaplatin for patients with recurrent and metastatic nasopharyngeal carcinoma.
Peng PJ; Lv BJ; Tang C; Liao H; Lin Z; Liu YM; Wang ZH; Wang SY; Cheng ZB
Drug Des Devel Ther; 2015; 9():6401-5. PubMed ID: 26677316
[TBL] [Abstract][Full Text] [Related]
52. Phase II study of gefitinib for the treatment of recurrent and metastatic nasopharyngeal carcinoma.
Chua DT; Wei WI; Wong MP; Sham JS; Nicholls J; Au GK
Head Neck; 2008 Jul; 30(7):863-7. PubMed ID: 18213730
[TBL] [Abstract][Full Text] [Related]
53. Combination of docetaxel, ifosfamide and cisplatin (DIP) as a potential salvage chemotherapy for metastatic urothelial carcinoma.
Kakutani S; Fukuhara H; Taguchi S; Nagata M; Niimi A; Hattori M; Miyazaki H; Fujimura T; Nakagawa T; Kume H; Igawa Y; Homma Y
Jpn J Clin Oncol; 2015 Mar; 45(3):281-5. PubMed ID: 25425701
[TBL] [Abstract][Full Text] [Related]
54. Triplet combination with paclitaxel, cisplatin and 5-FU is effective in metastatic and/or recurrent nasopharyngeal carcinoma.
Chen C; Wang FH; An X; Luo HY; Wang ZQ; Liang Y; Zhang L; Li YH
Cancer Chemother Pharmacol; 2013 Feb; 71(2):371-8. PubMed ID: 23143190
[TBL] [Abstract][Full Text] [Related]
55. A prospective phase II trial of induction chemotherapy with docetaxel/cisplatin for Masaoka stage III/IV thymic epithelial tumors.
Park S; Ahn MJ; Ahn JS; Sun JM; Shim YM; Kim J; Choi YS; Kim K; Shin S; Ahn Y; Kwon OJ; Kim H; Lee SJ; Chang WJ; Park K
J Thorac Oncol; 2013 Jul; 8(7):959-66. PubMed ID: 23722169
[TBL] [Abstract][Full Text] [Related]
56. Anti-epidermal growth factor receptor (EGFR) monoclonal antibody combined with cisplatin and 5-fluorouracil in patients with metastatic nasopharyngeal carcinoma after radical radiotherapy: a multicentre, open-label, phase II clinical trial.
Zhao C; Miao J; Shen G; Li J; Shi M; Zhang N; Hu G; Chen X; Hu X; Wu S; Chen J; Shao X; Wang L; Han F; Mai H; Chua MLK; Xie C
Ann Oncol; 2019 Apr; 30(4):637-643. PubMed ID: 30689735
[TBL] [Abstract][Full Text] [Related]
57. A combined therapy with docetaxel and nedaplatin for relapsed and metastatic esophageal carcinoma.
Matsumoto H; Hirabayashi Y; Kubota H; Murakami H; Higashida M; Haruma K; Hiratsuka J; Nakamura M; Hirai T
Anticancer Res; 2012 May; 32(5):1827-31. PubMed ID: 22593469
[TBL] [Abstract][Full Text] [Related]
58. [Preliminary result of multi-center clinical trial on the docetaxel, 5-Fu and DDP in the treatment of advanced, recurrent or metastatic nasopharyngeal carcinoma].
Huang HQ; Cai QQ; Lin XB; Wang AL; Bu Q; Hu XH; Pan ZH; Li YH; Shuang YR; Guan ZZ
Zhonghua Zhong Liu Za Zhi; 2008 Apr; 30(4):314-6. PubMed ID: 18788641
[TBL] [Abstract][Full Text] [Related]
59. Retrospective Analysis on the Feasibility and Efficacy of Docetaxel-Cisplatin Therapy for Recurrent Endometrial Cancer.
Ninomiya T; Yamagami W; Susumu N; Makabe T; Sakai K; Wada M; Takigawa A; Chiyoda T; Nomura H; Kataoka F; Hirasawa A; Banno K; Aoki D
Anticancer Res; 2016 Apr; 36(4):1751-8. PubMed ID: 27069155
[TBL] [Abstract][Full Text] [Related]
60. Phase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma.
Xue C; Huang Y; Huang PY; Yu QT; Pan JJ; Liu LZ; Song XQ; Lin SJ; Wu JX; Zhang JW; Zhao HY; Xu F; Liu JL; Hu ZH; Zhao LP; Zhao YY; Wu X; Zhang J; Ma YX; Zhang L
Ann Oncol; 2013 Apr; 24(4):1055-61. PubMed ID: 23172635
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
